GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (XSAT:SPAG BTA) » Definitions » Cyclically Adjusted Price-to-FCF

Spago Nanomedical AB (XSAT:SPAG BTA) Cyclically Adjusted Price-to-FCF : (As of Jul. 23, 2025)


View and export this data going back to . Start your Free Trial

What is Spago Nanomedical AB Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Spago Nanomedical AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Cyclically Adjusted Price-to-FCF Chart

Spago Nanomedical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Spago Nanomedical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Spago Nanomedical AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Spago Nanomedical AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Spago Nanomedical AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.782/132.8245*132.8245
=-1.782

Current CPI (Mar. 2025) = 132.8245.

Spago Nanomedical AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.620 99.995 -0.824
201509 -0.379 100.228 -0.502
201512 -0.062 100.276 -0.082
201603 -0.803 100.751 -1.059
201606 -0.500 101.019 -0.657
201609 -0.499 101.138 -0.655
201612 -0.378 102.022 -0.492
201703 -0.457 102.022 -0.595
201706 -0.661 102.752 -0.854
201709 -0.409 103.279 -0.526
201712 -0.616 103.793 -0.788
201803 -0.795 103.962 -1.016
201806 -0.247 104.875 -0.313
201809 -1.044 105.679 -1.312
201812 -0.828 105.912 -1.038
201903 -0.621 105.886 -0.779
201906 -1.950 106.742 -2.426
201909 -0.994 107.214 -1.231
201912 -2.338 107.766 -2.882
202003 -0.993 106.563 -1.238
202006 -1.634 107.498 -2.019
202009 -1.164 107.635 -1.436
202012 -1.413 108.296 -1.733
202103 -1.804 108.360 -2.211
202106 -1.989 108.928 -2.425
202109 -2.709 110.338 -3.261
202112 -3.363 112.486 -3.971
202203 -3.031 114.825 -3.506
202206 -2.720 118.384 -3.052
202209 -2.757 122.296 -2.994
202212 -2.087 126.365 -2.194
202303 -4.713 127.042 -4.928
202306 -3.775 129.407 -3.875
202309 -1.441 130.224 -1.470
202312 -2.567 131.912 -2.585
202403 -2.923 132.205 -2.937
202406 -2.522 132.716 -2.524
202409 -2.115 132.304 -2.123
202412 -2.054 132.987 -2.051
202503 -1.782 132.825 -1.782

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Spago Nanomedical AB  (XSAT:SPAG BTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Spago Nanomedical AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines